Multimorbidity, i.e. multiple simultaneous medical conditions, increases steadily in prevalence beyond the age of 70 years. As the European population ages, the number of older people with multimorbidity will inevitably increase in tandem. Multimorbidity, is a strong predictor of multiple medications, so-called polypharmacy (PP), which is recognized as the single greatest risk factor for adverse drug reactions (ADRs). The project aims to:
- Develop a highly-powered and efficient software engine (SENATOR) capable of individually screening the clinical status and pharmacological and non- pharmacological therapy of older people with multimorbidity in order to define optimal drug therapy, highlight ADR risk, indicate best value drug brand for selection and provide advice on appropriate non-pharmacological therapy.
- Perform a randomized controlled trial to examine the efficacy of SENATOR in reducing ADRs.
- Assess the cost-effectiveness of SENATOR-guided optimization of drug and non-drug therapy
- Develop SENATOR as a commercial software product for the healthcare software market.
The Senator Consortium
Nine of the 12 work packages are now active. Early work includes analysis of data on ADRs in the UCC Older Person ADR database and development of the Adverse Drug Reaction Risk in Older People scale.
The SENATOR project is funded as an FP7 project from 2013 through to 2017. Funding approved: 5.938 Million Euro over 60 months.